Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3117391 in moderate to severe active rheumatoid arthritis
2015-005800-27Phase 2Terminated
- Sponsor
- GSK
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing GSK3117391 with Placebo (2 arms). Primary endpoint: Change from baseline in DAS28-CRP. Started Oct 2016; status: terminated.
02
Drugs
GSK3117391
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2015-005800-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005800-27.